Abstract
Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.
| Original language | English (US) |
|---|---|
| Title of host publication | Handbook of Experimental Pharmacology |
| Publisher | Springer New York LLC |
| Pages | 229-250 |
| Number of pages | 22 |
| Volume | 240 |
| DOIs | |
| State | Published - 2017 |
Publication series
| Name | Handbook of Experimental Pharmacology |
|---|---|
| Volume | 240 |
| ISSN (Print) | 0171-2004 |
| ISSN (Electronic) | 1865-0325 |
Fingerprint
Keywords
- ATP
- Cardiolipin
- Kidney
- Mitochondria
ASJC Scopus subject areas
- Biochemistry
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
The emerging role of mitochondrial targeting in kidney disease. / Eirin, Alfonso; Lerman, Amir; Lerman, Lilach O.
Handbook of Experimental Pharmacology. Vol. 240 Springer New York LLC, 2017. p. 229-250 (Handbook of Experimental Pharmacology; Vol. 240).Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - The emerging role of mitochondrial targeting in kidney disease
AU - Eirin, Alfonso
AU - Lerman, Amir
AU - Lerman, Lilach O
PY - 2017
Y1 - 2017
N2 - Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.
AB - Renal disease affects millions of people worldwide, imposing an enormous financial burden for health-care systems. Recent evidence suggests that mitochondria play an important role in the pathogenesis of different forms of renal disease, including genetic defects, acute kidney injury, chronic kidney disease, aging, renal tumors, and transplant nephropathy. Renal mitochondrial abnormalities and dysfunction affect several cellular pathways, leading to increased oxidative stress, apoptosis, microvascular loss, and fibrosis, all of which compromise renal function. Over recent years, compounds that specifically target mitochondria have emerged as promising therapeutic options for patients with renal disease. Although the most compelling evidence is based on preclinical studies, several compounds are currently being tested in clinical trials. This chapter provides an overview of the involvement of mitochondrial dysfunction in renal disease and summarizes the current knowledge on mitochondria-targeted strategies to attenuate renal disease.
KW - ATP
KW - Cardiolipin
KW - Kidney
KW - Mitochondria
UR - http://www.scopus.com/inward/record.url?scp=85027396088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027396088&partnerID=8YFLogxK
U2 - 10.1007/164_2016_6
DO - 10.1007/164_2016_6
M3 - Chapter
C2 - 27316914
AN - SCOPUS:85027396088
VL - 240
T3 - Handbook of Experimental Pharmacology
SP - 229
EP - 250
BT - Handbook of Experimental Pharmacology
PB - Springer New York LLC
ER -